Terapi Kanker Payudara Stadium Lanjut HER2 (+)

Authors

  • Hastarita Lawrenti Dokter umum

DOI:

https://doi.org/10.55175/cdk.v50i10.915

Keywords:

HER2, breast cancer, advanced stage

Abstract

Approximately 15-20% of breast cancers harbor human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. This subtype of breast cancer is associated with aggressive behavior, high recurrence rates, and worse prognosis. However, with the introduction of HER2-targeted therapy, trastuzumab, the survival rates have greatly improved. In patients with HER2 positive advanced disease, taxane in combination with trastuzumab and pertuzumab is given in the first-line setting. In the second-line setting and beyond, several emerging anti-HER2 therapies are becoming available including trastuzumab deruxtecan, tucatinib, T-DM1, neratinib, lapatinib, pyrotinib, margetuximab.

Downloads

Download data is not yet available.

References

Martinez-Saez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17:594-604.

Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70:355-74.

Bartelemy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE. Pertuzumab: Development beyond breast cancer. Anticancer Res. 2014;34:1483-92.

Landaverde D, Verma S. Recent treatment advances in HER2-positive metastatic breast cancer: A clinical approach. Clin Pract. 2012;9(3):287-99.

Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open 2022 doi: 10.1016/j.esmoop.2021.100343.

Swain SM, Baselga J, Kim SB, Ro JS, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-34.

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-30.

Martinez MT, Perez-Fidalgo JA, Martin-Martorell P, Cejalvo JM, Pons V, Bermejo B, et al. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Crit Rev Oncol/Hematol. 2016;97:96-106.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743-54.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.

Li LX, Zhang D, Liu BL, Lv D, Zhai JT, Guan XW, et al. Antibody-drug conjugates in HER2-positive breast cancer. Chinese Medical Journal 2022;135(3):261-7.

Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on trastuzumab deruxtecan (DS-8201, T-DXd) for HER2 mutation positive non-small cell lung cancer. Lung Cancer: Targets and Therapy 2021;12:103-14.

Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Ann Pharmacother. 2021 doi: 10.1177/1060028021998320.

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;402:105-17.

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.

Trastuzumab deruxtecan. Product Information [FDA]. 2022 [cited 2022 May 29]. Available from: www.fda.gov.

Jacobson A. Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases. The Oncologist 2022;27(Suppl 1):S3-4.

Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12:1-9.

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.

Shah M, Wedam S, Cheng J, Fiero MH, Xia HM, Li F, et al. FDA approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:1220-6.

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38:3138-49.

Xu BH, Yan M, Hu XC, Feng JF, Ouyang QC, Tong ZS, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicenter, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351-60.

Blair HA. Pyrotinib: First global approval. Drugs 2018 doi: 10.1007/s40265-018-0997-0.

Schlam I, Nunes R, Lynce F. Profile of margetuximab: Evidence to date in the targeted treatment of metastatic HER2-positive breast cancer. Onco Targets and Therapy 2022;15:471-8.

Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 doi: 10.1200/JCO.21.02937.

NCCN clinical practice guidelines in oncology. Breast cancer. Version 4.2023 [cited 2023 May 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:2612-35.

Downloads

Published

02-10-2023

How to Cite

Lawrenti, H. (2023). Terapi Kanker Payudara Stadium Lanjut HER2 (+). Cermin Dunia Kedokteran, 50(10), 565–569. https://doi.org/10.55175/cdk.v50i10.915